Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148737 | 0.80 | KDM4E (0.39) | KDM4EHPGDSMN1; SMN2NFKB1LMNA | |
| SCHEMBL5888254 | 0.80 | L3MBTL1 (0.41) | KDM4EHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL15065620 | 0.79 | CYP1A2 (0.35) | — | |
| SCHEMBL16117755 | 0.77 | — | — | |
| SCHEMBL13718235 | 0.73 | SMN1; SMN2 (0.43) | KDM4EHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL18142979 | 0.70 | TDP1 (0.36) | KDM4EHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16398542 | 0.69 | CYP1A2 (0.36) | KDM4EHPGDSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL15065438 | 0.66 | — | — | |
| SCHEMBL23817025 | 0.65 | CHRNB2 (0.30) | — | |
| SCHEMBL24500185 | 0.65 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229095-A1 | Sexual disorders | PDE3B, PDE3A, PDE2A | KDM4E 210/4885HPGD 225/4885SMN1; SMN2 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.